Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway

類似資料

• Concomitant BET and MAPK blockade for effective treatment of ovarian cancer
  著者:: Jing, Ying, 等
  出版事項: (2015)
• Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
  著者:: Jacobsen, Kirstine, 等
  出版事項: (2017)
• Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer
  著者:: Ma, Pengfei, 等
  出版事項: (2017)
• Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy 
in Advanced NSCLC Patients with EGFR Mutations
  著者:: Minjiang CHEN, 等
  出版事項: (2019-02-01)
• Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
  著者:: Xu, Haiyuan, 等
  出版事項: (2019)